References
- IshizakiTHoraiYReview article: cytochrome P450 and the metabolism of proton pump inhibitors – emphasis on rabeprazoleAliment Pharmacol Ther199913273610491726
- RenbergLSimonssonRHoffmannKJIdentification of two main urinary metabolites of [14C]omeprazole in humansDrug Metab Dispos19891769762566473
- AnderssonTMinersJOVeroneseMEIdentification of human liver cytochrome P450 isoforms mediating omeprazole metabolismBr J Clin Pharmacol19933652153012959268
- MouradMWallemacqPDe MeyerMBiotransformation enzymes and drug transporters pharmacogenetics in relation to immunosuppressive drugs: impact on pharmacokinetics and clinical outcomeTransplantation200885S19S2418401258
- TsuchiyaNSatohSTadaHInfluence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipientsTransplantation2004781182118715502717
- HuYFHeJChenGLCYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese populationClin Chim Acta200535318719215698606
- ChristiansUSchmidtGBaderAIdentification of drugs inhibiting the in vitro metabolism of tacrolimus by human liver microsomesBr J Clin Pharmacol1996411871908866917
- MatsudaHIwasakiKShiragaTTozukaZHataTGuengerichFPInteractions of FK506 (tacrolimus) with clinically important drugsRes Commun Mol Pathol Pharmacol19969157648824931
- RostKLRootsINonlinear kinetics after high-dose omeprazole caused by saturation of genetically variable CYP2C19Hepatology199623149114978675169
- PascualJMarcénROreaOEInteraction between omeprazole and tacrolimus in renal allograft recipients: a clinical-analytical studyTransplant Proc2005373752375316386527
- TakahashiKYanoIFukuharaYDistinct effects of omeprazole and rabeprazole on the tacrolimus blood concentration in a kidney transplant recipientDrug Metab Pharmacokinet20072244144418159131
- LemahieuWPMaesBDVerbekeKVanrenterghemYImpact of gastric acid suppressants on cytochrome P450 3A4 and P-glycoprotein: consequences for FK506 assimilationKidney Int2005671152116015698457
- van SchaikRHvan der HeidenIPvan den AnkerJNLindemansJCYP3A5 variant allele frequencies in Dutch CaucasiansClin Chem2002481668167112324482
- EvansWEMcLeodHLPharmacogenomics-drug disposition, drug targets, and side effectsN Engl J Med200334853854912571262
- ArvanitidisKRagiaGIordanidouMGenetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek populationFundam Clin Pharmacol20072141942617635181
- MoreauCDebrayDLoriotMATaburetAMFurlanVInteraction between tacrolimus and omeprazole in a pediatric liver transplant recipientTransplantation200681487488 Erratum in: Transplantation 2006;82:1382.16477241
- TakahashiKMotohashiHYonezawaALansoprazole-tacrolimus interaction in Japanese transplant recipient with CYP2C19 polymorphismAnn Pharmacother20048791794 Epub 2004 Mar 9.15010519
- ItagakiFHommaMYuzawaKFukaoKKohdaYDrug interaction of tacrolimus and proton pump inhibitors in renal transplant recipients with CYP2C19 gene mutationTransplant Proc2002342777277812431607
- FurutaTOhashiKKosugeKCYP2C19 genotype status and effect of omeprazole on intragastric pH in humansClin Pharmacol Ther19996555256110340921
- De MoraisSMWilkinsonGRBlaisdellJMeyerUANakamuraKGoldsteinJAIdentification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in JapaneseMol Pharmacol1994465945987969038
- HunfeldNGMathotRATouwDJEffect of CYP2C19*2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in CaucasiansBr J Clin Pharmacol200865752760 Epub 2008 Jan 30.18241283
- van GelderTDrug interactions with tacrolimusDrug Saf20022570771212167066
- HosohataKMasudaSKatsuraTImpact of intestinal CYP2C19 genotypes on the interaction between tacrolimus and omeprazole, but not lansoprazole, in adult living-donor liver transplant patientsDrug Metab Dispos200937821826Epub 2009 Jan 12.19139162